Yazar "Onat, A. M." seçeneğine göre listele
Listeleniyor 1 - 6 / 6
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe ARE CLINICAL FEATURES IN LOFGREN'S SYNDROME-RELATED ERYTHEMA NODOSUM DIFFERENT FROM IDIOPATHIC ERYTHEMA NODOSUM?(Mattioli 1885, 2012) Donmez, S.; Kisacik, B.; Pamuk, O. N.; Pehlivan, Y.; Aydogdu, E.; Yurekli, O. A.; Onat, A. M.Background and Objectives: We retrospectively evaluated acute sarcoidosis (Lofgren's syndrome) patients diagnosed at 2 centers and compared the clinical features of Lofgren's syndrome (LS) related erythema nodosum (EN) to patients with idiopathic IEN who were diagnosed within the same time frame. Methods: Thirty patients (10 males, 20 females) who were diagnosed with LS and were being followed up for the last 8 years at 2 centers were included. Thirty patients (4 males, 26 females) who were admitted to the rheumatology outpatient clinics for IEN during that time period were taken as controls. The clinical and laboratory features at the initial admission, treatment modalities and response were recorded. Results: Twentyfour (80%) patients with LS related EN had arthritis and/or arthralgia. Fifteen of them had only findings of periarticular ankle inflammation and 4 had polyarthritis. When LS related EN patients were compared to IEN patients, the former group had more arthritis and/or arthralgia (p<0.001), leucocytosis (p=0.02), lymphopenia (p=0.005) and thrombocytosis (p=0.05), and higher ESR (p=0.02). Twentyfive (83.3%) patients with LS related EN were administered oral corticosteroids. In 21 patients, hilar lymphadenopathy disappeared on control chest x-ray and CT; in 3 patients, minimal residual lymph node enlargement was persistent. During a median follow-up of 54 months (range: 10-84 months), none of the LS related EN patients had clinical relapse. Conclusions: Apart from BHL, arthritis and/or arthralgia especially periarticular ankle inflammation is the feature which could be used to differentiate LS related EN from IEN. There is more need for steroids in LS patients and the symptoms quickly resolve with steroids.Öğe THE COMPARATIVE ONE-YEAR DRUG SURVIVAL RATE OF TUMOR NECROSIS FACTOR INHIBITORS IN PATIENTS WITH RHEUMATOID ARTHRITIS AND ANKYLOSING SPONDYLITIS; RESULTS FROM TURKBIO REGISTRY(Bmj Publishing Group, 2014) Sari, I.; Kalyoncu, U.; Onat, A. M.; Pamuk, O. N.; Karadag, O.; Kisacik, B.; Senel, S.[Abstract Not Available]Öğe THE DATABASE FOR SYSTEMIC SCLEROSIS IN TURKEY (SYS-WATCH): ANALYSIS OF PATIENTS WITH ELEVATED PULMONARY ARTERIAL PRESSURES ON ECHOCARDIOGRAPHIC SCREENING FOR PULMONARY HYPERTENSION(Clinical & Exper Rheumatology, 2010) Inanc, M.; Birlik, M.; Onat, A. M.; Ozbalkan, Z.; Yarguku, F.; Kasifoglu, T.; Pamuk, O. N.[Abstract Not Available]Öğe PARANEOPLASTIC ARTHRITIS: A MULTI-CENTERED EXPERIENCE(Bmj Publishing Group, 2013) Kisacik, B.; Onat, A. M.; Kasifoglu, T.; Pehlivan, Y.; Pamuk, O. N.; Dalkilic, E.; Donmez, S.[Abstract Not Available]Öğe THE SURVIVAL AND PROGNOSTIC FACTORS OF PATIENTS WITH SYSTEMIC SCLEROSIS: EXPERIENCE OF TWO CENTERS(Bmj Publishing Group, 2015) Onat, A. M.; Zengin, O.; Balci, M. A.; Kimyon, G.; Kisacik, B.; Pamuk, O. N.[Abstract Not Available]Öğe Validity and reliability of the Lupus QoL index in Turkish systemic lupus erythematosus patients(Sage Publications Ltd, 2015) Pamuk, O. N.; Onat, A. M.; Donmez, S.; Mengus, C.; Kisacik, B.Background Systemic lupus erythematosus (SLE) patients have seriously impaired quality of life (QoL). In addition to activity and damage indices used in the past, tools to evaluate QoL in SLE have been developed in recent years. In this study, we test the validity of the Turkish version of the Lupus-QoL (LupusQoL-TR) score, and investigate its association with clinical findings and activity indices. Methods A total of 132 patients diagnosed with SLE according to ACR 1997 criteria were included. The clinical and demographic features, and biochemical data were retrieved from hospital records. SLE Disease Activity Index (SLEDAI) and damage score (SLICC-ACR) were determined at the time of administration of Lupus-QoL questionnaire. The Lupus-QoL includes 34 questions divided into eight domains. We reevaluated the LupusQoL-TR and pretested its understandability. SLE patients were concomitantly administered the LupusQoL-TR and generic SF-36. Internal consistency, test-retest reliability, convergent and discriminant validity were calculated. Results The mean age of our SLE patients was 37.912.8 years. Internal consistency reliability ranged from 0.88 to 0.93, and test-retest reliability from 0.84 to 0.94. LupusQoL-related domains in SF-36 were correlated (from 0.66 to 0.74). Most LupusQoL-TR domains, except planning, were able to discriminate between active and inactive SLE groups. Scores in all domains of the LupusQoL-TR were found to be discriminative for patients with and without damage according to SLICC-ACR score. Conclusion The LupusQoL-TR was found to be a valid patient-reported outcome measure method when evaluating QoL in Turkish SLE patients.